# Enveda

Enveda is a company headquartered in Boulder, United States, founded in 2019.



Canonical: https://uniquebase.ai/companies/enveda
Stable identifier: UB-C5443
Snapshot captured: 2026-10-15T14:23:27.067Z
English updated: 2026-10-15T17:10:20.164Z

## Funding

Listed 2 records.
Latest: $311M (Series E), 2026-09-24.

- 2026-09-24 · $311M · Series E · Alderline Group, Baillie Gifford, Catalio Capital Management, Digitalis Ventures, Dimension, Durable Capital Partners, FPV Ventures, ICONIQ Growth, Kinnevik, Lifeforce Capital, Lightspeed Venture Partners, Lux Capital, Premji Invest, Surveyor Capital, T.Rowe Price investment Management, True Ventures
  > On 2026-09-24, according to Xiniu Data, Enveda Biosciences completed Series E financing, raising USD 311 million. Investors were lead investor Catalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed and others. The company is a developer of AI natural product drugs. (translated source brief)
- 2026-09-23 · $311M · Series E · Catalio Capital Management · https://presspool.ai/ai-startup-funding/week-of-2026-09-21
  > On 2026/9/23, Presspool reported that US AI drug discovery company Enveda had raised USD 311 million in Series E funding led by Catalio Capital Management. (translated source brief)

## Valuation

Listed 2 records.

- 2026-09-24 · amount unavailable · Series E · Alderline Group, Baillie Gifford, Catalio Capital Management, Digitalis Ventures, Dimension, Durable Capital Partners, FPV Ventures, ICONIQ Growth, Kinnevik, Lifeforce Capital, Lightspeed Venture Partners, Lux Capital, Premji Invest, Surveyor Capital, T.Rowe Price investment Management, True Ventures
  > On 2026-09-24, according to Xiniu Data, Enveda Biosciences completed Series E financing, raising USD 311 million. Investors were lead investor Catalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed and others. The company is a developer of AI natural product drugs. (translated source brief)
- 2026-09-23 · amount unavailable · Series E · Catalio Capital Management · https://presspool.ai/ai-startup-funding/week-of-2026-09-21
  > On 2026/9/23, Presspool reported that US AI drug discovery company Enveda had raised USD 311 million in Series E funding led by Catalio Capital Management. (translated source brief)

## Revenue

No revenue records are listed yet.


## Team

- [Viswa Colluru](/people/viswa-colluru)

## Products

No published products profiles are linked yet.

## Investors

- [Alderline Group](/institutions/alderline-group)
- [Baillie Gifford](/institutions/baillie-gifford)
- [Catalio Capital Management](/institutions/catalio-capital-management)
- [Digitalis Ventures](/institutions/digitalis-ventures)
- [Dimension](/institutions/dimension)
- [Durable Capital Partners](/institutions/durable-capital-partners)
- [FPV Ventures](/institutions/fpv-ventures)
- [ICONIQ Growth](/institutions/iconiq-growth)
- [Kinnevik](/institutions/kinnevik)
- [Lifeforce Capital](/institutions/lifeforce-capital)
- [Lightspeed Venture Partners](/institutions/lightspeed-venture-partners)
- [Lux Capital](/institutions/lux-capital)
- [Premji Invest](/institutions/premji-invest)
- [Surveyor Capital](/institutions/surveyor-capital)
- [T.Rowe Price investment Management](/institutions/t-rowe-price-investment-management)
- [True Ventures](/institutions/true-ventures)

## Sources

- No source links are available for this profile.